- Home
- BCSF vs IVA Comparison
BCSF vs IVA Comparison
Compare BCSF & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- IVA
- Stock Information
- Founded
- BCSF 2015
- IVA 2011
- Country
- BCSF United States
- IVA France
- Employees
- BCSF N/A
- IVA N/A
- Industry
- BCSF Finance/Investors Services
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- IVA Health Care
- Exchange
- BCSF Nasdaq
- IVA Nasdaq
- Market Cap
- BCSF 901.0M
- IVA 769.0M
- IPO Year
- BCSF 2018
- IVA 2020
- Fundamental
- Price
- BCSF $14.07
- IVA $4.03
- Analyst Decision
- BCSF Buy
- IVA Strong Buy
- Analyst Count
- BCSF 2
- IVA 7
- Target Price
- BCSF $16.50
- IVA $16.57
- AVG Volume (30 Days)
- BCSF 393.1K
- IVA 354.0K
- Earning Date
- BCSF 11-10-2025
- IVA 09-29-2025
- Dividend Yield
- BCSF 12.71%
- IVA N/A
- EPS Growth
- BCSF N/A
- IVA N/A
- EPS
- BCSF 1.66
- IVA N/A
- Revenue
- BCSF $283,687,000.00
- IVA $19,929,536.00
- Revenue This Year
- BCSF N/A
- IVA N/A
- Revenue Next Year
- BCSF N/A
- IVA N/A
- P/E Ratio
- BCSF $8.52
- IVA N/A
- Revenue Growth
- BCSF N/A
- IVA N/A
- 52 Week Low
- BCSF $13.20
- IVA $2.11
- 52 Week High
- BCSF $19.21
- IVA $7.98
- Technical
- Relative Strength Index (RSI)
- BCSF 46.99
- IVA 38.70
- Support Level
- BCSF $14.01
- IVA $3.79
- Resistance Level
- BCSF $14.55
- IVA $7.98
- Average True Range (ATR)
- BCSF 0.28
- IVA 0.75
- MACD
- BCSF 0.08
- IVA -0.12
- Stochastic Oscillator
- BCSF 62.20
- IVA 5.84
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.